

Zaoqu Liu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2611214/publications.pdf>

Version: 2024-02-01

54
papers

1,091
citations

516710

16
h-index

580821

25
g-index

67
all docs

67
docs citations

67
times ranked

302
citing authors

#	ARTICLE	IF	CITATIONS
1	125I seeds inhibit proliferation and promote apoptosis in cholangiocarcinoma cells by regulating the AGR2-mediated p38 MAPK pathway. <i>Cancer Letters</i> , 2022, 524, 29-41.	7.2	9
2	A New Trend in Cancer Treatment: The Combination of Epigenetics and Immunotherapy. <i>Frontiers in Immunology</i> , 2022, 13, 809761.	4.8	29
3	Integrative analysis from multi-center studies identifies a consensus machine learning-derived lncRNA signature for stage II/III colorectal cancer. <i>EBioMedicine</i> , 2022, 75, 103750.	6.1	73
4	Stemness Refines the Classification of Colorectal Cancer With Stratified Prognosis, Multi-Omics Landscape, Potential Mechanisms, and Treatment Options. <i>Frontiers in Immunology</i> , 2022, 13, 828330.	4.8	32
5	Clinical Significance and Immune Landscape of a Pyroptosis-Derived lncRNA Signature for Glioblastoma. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 805291.	3.7	14
6	EGR1 and KLF4 as Diagnostic Markers for Abdominal Aortic Aneurysm and Associated With Immune Infiltration. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 781207.	2.4	7
7	Machine learning-based integration develops an immune-derived lncRNA signature for improving outcomes in colorectal cancer. <i>Nature Communications</i> , 2022, 13, 816.	12.8	192
8	Multi-omics landscape and clinical significance of a SMAD4-driven immune signature: Implications for risk stratification and frontline therapies in pancreatic cancer. <i>Computational and Structural Biotechnology Journal</i> , 2022, 20, 1154-1167.	4.1	12
9	Integrated Analysis of Multi-Omics Alteration, Immune Profile, and Pharmacological Landscape of Pyroptosis-Derived lncRNA Pairs in Gastric Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 816153.	3.7	15
10	Gene Expression Profile Reveals a Prognostic Signature of Non-MSI-H/pMMR Colorectal Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 790214.	3.7	5
11	TP53 /KRAS Co-Mutations Create Divergent Prognosis Signatures in Intrahepatic Cholangiocarcinoma. <i>Frontiers in Genetics</i> , 2022, 13, 844800.	2.3	4
12	Antigen Presentation Machinery Signature-Derived CALR Mediates Migration, Polarization of Macrophages in Glioma and Predicts Immunotherapy Response. <i>Frontiers in Immunology</i> , 2022, 13, 833792.	4.8	5
13	Development and Validation of Ischemic Events Related Signature After Carotid Endarterectomy. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 794608.	3.7	5
14	Large-Scale Single-Cell and Bulk Sequencing Analyses Reveal the Prognostic Value and Immune Aspects of CD147 in Pan-Cancer. <i>Frontiers in Immunology</i> , 2022, 13, 810471.	4.8	16
15	CAMOIP: a web server for comprehensive analysis on multi-omics of immunotherapy in pan-cancer. <i>Briefings in Bioinformatics</i> , 2022, 23, .	6.5	52
16	Intraoperative cone beam computed tomography of tracheal stenting for stenosis and fistula diseases: a retrospective cohort study. <i>Quantitative Imaging in Medicine and Surgery</i> , 2022, 12, 2709-2720.	2.0	1
17	Identify the Prognostic and Immune Profile of VSIR in the Tumor Microenvironment: A Pan-Cancer Analysis. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 821649.	3.7	4
18	The Comprehensive Analysis Identified an Autophagy Signature for the Prognosis and the Immunotherapy Efficiency Prediction in Lung Adenocarcinoma. <i>Frontiers in Immunology</i> , 2022, 13, 749241.	4.8	15

#	ARTICLE	IF	CITATIONS
19	Exploring Key Genes to Construct a Diagnosis Model of Dilated Cardiomyopathy. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 865096.	2.4	4
20	Prognostic Factors and Treatment Strategies for Elderly Patients with Malignant Meningioma: A SEER Population-Based Study. <i>Frontiers in Oncology</i> , 2022, 12, .	2.8	1
21	Transcriptome-Based Dissection of Intracranial Aneurysms Unveils an "Immuno-Thermal" Microenvironment and Defines a Pathological Feature-Derived Gene Signature for Risk Estimation. <i>Frontiers in Immunology</i> , 2022, 13, .	4.8	5
22	A Novel Thrombosis-Related Signature for Predicting Survival and Drug Compounds in Glioblastoma. <i>Journal of Oncology</i> , 2022, 2022, 1-16.	1.3	1
23	Roles of Bile-Derived Exosomes in Hepatobiliary Disease. <i>BioMed Research International</i> , 2021, 2021, 1-14.	1.9	6
24	Making timely remedial measures after TACE based on the results of cone-beam CT liver perfusion. <i>International Journal of Hyperthermia</i> , 2021, 38, 428-436.	2.5	4
25	LINC01296/miR-141-3p/ZEB1-ZEB2 axis promotes tumor metastasis via enhancing epithelial-mesenchymal transition process. <i>Journal of Cancer</i> , 2021, 12, 2723-2734.	2.5	16
26	LINC01272/miR-876/ITGB2 axis facilitates the metastasis of colorectal cancer via epithelial-mesenchymal transition. <i>Journal of Cancer</i> , 2021, 12, 3909-3919.	2.5	12
27	A novel immune classification reveals distinct immune escape mechanism and genomic alterations: implications for immunotherapy in hepatocellular carcinoma. <i>Journal of Translational Medicine</i> , 2021, 19, 5.	4.4	66
28	TTN/OBSCN "DoubleHit" predicts favourable prognosis, "immune-hot" subtype and potentially better immunotherapeutic efficacy in colorectal cancer. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 3239-3251.	3.6	34
29	Development and validation of a robust immune-related risk signature for hepatocellular carcinoma. <i>Medicine (United States)</i> , 2021, 100, e24683.	1.0	7
30	The Identification and Validation of Two Heterogenous Subtypes and a Risk Signature Based on Ferroptosis in Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 619242.	2.8	48
31	Microwave Ablation of Small Hepatic Metastases Using MR Guidance and Monitoring: Clinical Safety and Efficacy. <i>Cancer Management and Research</i> , 2021, Volume 13, 3357-3366.	1.9	2
32	Genomic Alteration Characterization in Colorectal Cancer Identifies a Prognostic and Metastasis Biomarker: FAM83A IDO1. <i>Frontiers in Oncology</i> , 2021, 11, 632430.	2.8	32
33	MR-guided microwave ablation of hepatocellular carcinoma (HCC): is general anesthesia more effective than local anesthesia?. <i>BMC Cancer</i> , 2021, 21, 562.	2.6	5
34	Association of RYR2 Mutation With Tumor Mutation Burden, Prognosis, and Antitumor Immunity in Patients With Esophageal Adenocarcinoma. <i>Frontiers in Genetics</i> , 2021, 12, 669694.	2.3	34
35	Establishment and experimental validation of an immune miRNA signature for assessing prognosis and immune landscape of patients with colorectal cancer. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 6874-6886.	3.6	29
36	A Comparative Study of Self-Expandable Metallic Stent Combined with Double 125I Seeds Strands or Single 125I Seeds Strand in the Treatment of Advanced Perihilar Cholangiocarcinoma with Malignant Obstructive Jaundice. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 4077-4086.	2.0	7

#	ARTICLE	IF	CITATIONS
37	Comprehensive Molecular Analyses of a Novel Mutational Signature Classification System with Regard to Prognosis, Genomic Alterations, and Immune Landscape in Glioma. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 682084.	3.5	29
38	CELF2 is a candidate prognostic and immunotherapy biomarker in triple-negative breast cancer and lung squamous cell carcinoma: A pan-cancer analysis. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 7559-7574.	3.6	11
39	Clinical Significance and Inflammatory Landscape of a Novel Recurrence-Associated Immune Signature in Stage II/III Colorectal Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 702594.	4.8	36
40	Development and clinical validation of a novel six-gene signature for accurately predicting the recurrence risk of patients with stage II/III colorectal cancer. <i>Cancer Cell International</i> , 2021, 21, 359.	4.1	28
41	Screening Prognosis-Related lncRNAs Based on WGCNA to Establish a New Risk Score for Predicting Prognosis in Patients with Hepatocellular Carcinoma. <i>Journal of Immunology Research</i> , 2021, 2021, 1-20.	2.2	6
42	Comprehensive Molecular Analyses of a Six-Gene Signature for Predicting Late Recurrence of Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 732447.	2.8	8
43	Clinical Application Value of Circulating Cell-free DNA in Hepatocellular Carcinoma. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 736330.	3.5	10
44	Hypoxia Molecular Characterization in Hepatocellular Carcinoma Identifies One Risk Signature and Two Nomograms for Clinical Management. <i>Journal of Oncology</i> , 2021, 2021, 1-20.	1.3	26
45	Derivation and Clinical Validation of a Redox-Driven Prognostic Signature for Colorectal Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 743703.	2.8	4
46	Computational Recognition and Clinical Verification of TGF- β -Derived miRNA Signature With Potential Implications in Prognosis and Immunotherapy of Intrahepatic Cholangiocarcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 757919.	2.8	22
47	Epigenetic Signaling of Cancer Stem Cells During Inflammation. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 772211.	3.7	12
48	Tumor suppressor gene mutations correlate with prognosis and immunotherapy benefit in hepatocellular carcinoma. <i>International Immunopharmacology</i> , 2021, 101, 108340.	3.8	23
49	Immune Landscape Refines the Classification of Colorectal Cancer With Heterogeneous Prognosis, Tumor Microenvironment and Distinct Sensitivity to Frontline Therapies. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 784199.	3.7	13
50	Molecular Characterization and Clinical Relevance of ALDH2 in Human Cancers. <i>Frontiers in Medicine</i> , 2021, 8, 832605.	2.6	4
51	Somatic mutations in homologous recombination pathway predict favourable prognosis after immunotherapy across multiple cancer types. <i>Clinical and Translational Medicine</i> , 2021, 11, e619.	4.0	31
52	An Integrated Fibrosis Signature for Predicting Survival and Immunotherapy Efficacy of Patients With Hepatocellular Carcinoma. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 766609.	3.5	9
53	Novel miRNA Predicts Survival and Prognosis of Cholangiocarcinoma Based on RNA-seq Data and In Vitro Experiments. <i>BioMed Research International</i> , 2020, 2020, 1-14.	1.9	14
54	ALOX12: A Novel Insight in Bevacizumab Response, Immunotherapy Effect, and Prognosis of Colorectal Cancer. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	1